Citations

Showing 10 of 108152 citations.

Liver Transplantation for Acute Liver Failure Secondary to Acute Sickle Intrahepatic Cholestasis
Racho, Ronald G., Krishna, Murli , Canabal, Juan, Canabal, Juan M, Keaveny, Andrew P.

Mayo Clinic

American Journal of Gastroenterology | July 30, 2019 | Volume: 115 | Issue: 6 | Pages: 809-809

10.14309/ajg.0000000000000345 | PMID 31365350 Get It

In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma
Yang, Man , Hlady, Ryan A. , Ho, Thai H. , Robertson, Keith D. , Zhou, Dan , Ho, Thai , Robertson, Keith D

Mayo Clinic

Cancer Medicine | July 30, 2019 | Volume: 8 | Issue: 12 | Pages: 5760-5768

10.1002/cam4.2402 | PMID 31361072 Get It

AbstractThere are currently no effective treatments for advanced‐stage papillary renal cell carcinoma (PRCC). The goal of this study is to define potential DNA methylation‐based markers and treatment targets for advanced‐stage type 2 PRCC. Progressive DNA methylation changes and copy number variation (CNV) from localized to advanced‐stage type 2 PRCC are analyzed by using methylation data generated by TCGA's kidney renal papillary cell carcinoma (TCGA‐KIRP, 450k array) project. Survival analyses are performed for the identified biomarkers and genes with CNV. In addition, expression of the corresponding genes is investigated by RNA‐seq analysis. Progressive methylation changes in several CpGs from localized to advanced‐stage type 2 PRCC are observed. Four CpGs (cg00489401, cg27649239, cg20555674, and cg07196505) in particular are identified as markers for differentiating between localized and advanced‐stage type 2 PRCC. Copy number analysis reveals that copy gain of PTK7 mostly occurs in advanced‐stage type 2 PRCC. Both the four CpG methylation changes and PTK7 copy number gain are associated with patient survival. RNA‐seq analysis demonstrates that PTK7 copy gain leads to higher PTK7 expression relative to tumors without copy number gain. Moreover, PTK7 is significantly upregulated from localized to advanced‐stage type 2 PRCC and is linked to cancer cell invasion. In conclusion, DNA methylation markers that differentiate between localized and advanced‐stage type 2 PRCC may serve as useful markers for disease staging or outcome, while PTK7 copy gain represents a potential treatment target for advanced‐stage type 2 PRCC. Stepwise methylation changes and copy number gain also associate with disease stage in PRCC patients.
Hamstring Injury Trends in Major and Minor League Baseball: Epidemiological Findings From the Major League Baseball Health and Injury Tracking System
Okoroha, Kelechi R. , Conte, Stan, Lizzio, Vincent A. , Li, Bernard, Makhni, Eric Chugh , Camp, Christopher L. , Ahmad, Christopher S.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 30, 2019 | Volume: 7 | Issue: 7 | Pages: No page available

10.1177/2325967119861064 | PMID 31431899 Get It

Background: Hamstring strains are the most common injury for professional baseball players and can result in significant time on the disabled list. To date, no study has reported the current trends in hamstring strains in professional baseball. Hypothesis: Professional baseball players would have an increased incidence of hamstring strains from 2011 through 2016. Study Design: Descriptive epidemiology study. Methods: Injury data were prospectively collected from 2011 through 2016 for every Major League Baseball (MLB) and Minor League Baseball (MiLB) team and was recorded in the MLB Health and Injury Tracking System. Data collected for this study included date of injury, activity during injury, time lost, primary injury or reinjury status, and imaging findings as well as player demographic information related to level of play, age, and position for all hamstring injury events. Injury rates were reported as hamstring injuries per number of games. Results: From 2011 to 2016, there were 2633 hamstring strains in professional baseball players. The rate of hamstring strains increased in MLB from a low of 1 injury every 39 games in 2011 to a high of 1 injury every 30 games in 2016. In MiLB, there were 2192 hamstring strains, with 1 injury every 35 games in 2011 compared with 1 injury every 30 games in 2016. The majority of injuries occurred in the infielder positions (37.5%) and resulted from base running (>50%), most commonly from home to first base. The most common hamstring injury was a grade 2 injury to the distal biceps femoris. The mean time missed after a hamstring injury was 14.5 days. Grade 3 and grade 2 hamstring strains resulted in significantly more days missed compared with grade 1 injuries ( P = .005 and P = .002, respectively). The rate of recurrent hamstring injuries was 16.3% for MLB and 14.2% for MiLB. Recurrent hamstring injuries resulted in more time lost than primary injuries (mean, 16.4 vs 14.5 days, respectively; P = .02). A total of 42 injuries were treated with platelet-rich plasma, and 19 were treated with surgery. The number of injuries treated with platelet-rich plasma increased in successive years. Conclusion: The rate of hamstring strains in professional baseball players has increased over the past 6 years and has resulted in a significant loss of playing time. Study results indicated that these injuries are affected by injury characteristics, position played, running to first base, seasonal timing, and history of hamstring injuries.
Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
Mahipal, Amit , Tella, Sri Harsha , Kommalapati, Anuhya , Lim, Alexander, Mahipal, Amit , Kommalapati, Anuhya , Kim, Richard D.

Mayo Clinic

Cancers | July 30, 2019 | Volume: 11 | Issue: 8 | Pages: 1078

10.3390/cancers11081078 | PMID 31366113 Get It

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with dismal prognosis when diagnosed at advanced stages. Surgical resection of the primary tumor or orthotropic liver transplantation serves as a potential curative option. However, this approach is highly dependent on the hepatic reserve and baseline functional status of the patient. Liver directed therapies such as portal vein embolization (PVE), trans-arterial chemoembolization (TACE), and systemic chemotherapy are employed in non-surgical candidates. Sorafenib was the only approved systemic therapeutic agent for almost a decade until the recent approval of lenvatinib by the United States Food and Drug Administration (FDA) as an alternate first-line agent. Regorafenib, nivolumab, pembrolizumab and cabozantinib are approved by the FDA as second-line agents in patients who failed or could not tolerate sorafenib. Ramucirumab was recently FDA approved for the subset of patients that have high alfa-fetoprotein levels (>400 ng/mL). A better understanding of tumorigenesis and encouraging clinical trial results that evaluated immune-checkpoint inhibitors opened doors for immunotherapy in HCC. Immune checkpoint inhibitors have demonstrated a prolonged median overall and progression-free survival in a subset of patients with HCC. On-going translational and clinical research will hopefully provide us with a better understanding of tumor markers, genetic aberrations and other factors that determine the immunotherapy response in HCC. In this review, we sought to summarize the potential role and future directions of immunotherapy in the management of HCC.
Smoking Significantly Impacts Persistence Rates in Embolized Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia
Haddad, M , Bendel, Emily C. , Harmsen, William S. , Misra, Sanjay , Haddad, Mustafa M, Misra, Sanjay , Iyer, Vivek

Mayo Clinic

Radiology | July 30, 2019 | Volume: 292 | Issue: 3 | Pages: 762-770

10.1148/radiol.2019180978 | PMID 31361208 Get It

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats
Karau, Melissa J. , Schmidt-Malan, Suzannah M., Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Lehoux, Dario , Schuch, Raymond , Cassino, Cara, Patel, Robin , Mandrekar, Jayawant, Schuch, Raymond , Patel, Robin , Yan, Qun

Mayo Clinic

Antimicrobial Agents and Chemotherapy | July 30, 2019 | Volume: 63 | Issue: 10 | Pages: No page available

10.1128/aac.01235-19 | PMID 31358593 Get It

Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log 10 CFU/gram of bone, respectively.
FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology
Mao, Qinwen , Zheng, Xiaojing , Gefen, Tamar , Rogalskı, Emily , Spencer, Callen, Rademakers, Rosa , Fought, Angela J. , Kohler, Missia, Weıntraub, Sandra , Mesulam, Marek-Marsel, Bigio, Eileen H. , Xia, Haibin , Mesulam, Marek-Marsel, Mao, Qinwen

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | July 30, 2019 | Volume: 78 | Issue: 9 | Pages: 844-853

10.1093/jnen/nlz059 | PMID 31361008 Get It

Abstract Heterozygous loss-of-function mutations in the GRN gene lead to progranulin (PGRN) haploinsufficiency and cause frontotemporal lobar degeneration with TDP-43 pathology type A (FTLD-TDP type A). PGRN is a highly conserved, secreted glycoprotein and functions in the central nervous system as a key modulator of microglial function. Hence, altered microglial function caused by PGRN deficiency may be tied to the pathogenesis of FTLD-TDP. Our previous studies showed that haploinsufficiency of GRN mutations extends to microglial PGRN expression in the hippocampal CA1 region. In this study, we found that the CA1 sector was associated with less neuronal loss and more frequent TDP-43 inclusions in FTLD-TDP type A cases with GRN mutations than in sporadic cases. In addition, the CA1 region in GRN mutation cases contained more rod-like microglia, which also had reduced PGRN expression. These findings suggest that the profile of TDP-43 inclusions, neuronal number, and microgliosis in the CA1 sector of FTLD-TDP type A cases may be influenced by GRN gene expression status.
The role of microbiome in rheumatoid arthritis treatment
Bodkhe, Rahul , Balakrishnan, Baskar , Taneja, Veena , Taneja, Veena , Balakrishnan, Baskar

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | July 30, 2019 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1759720x19844632 | PMID 31431810 Get It

Rheumatoid arthritis (RA) is an autoimmune disorder with multifactorial etiology; both genetic and environmental factors are known to be involved in pathogenesis. Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an essential role in controlling disease progression and symptoms. DMARDs have immunomodulatory properties and suppress immune response by interfering in various pro-inflammatory pathways. Recent evidence has shown that the gut microbiota directly and indirectly modulates the host immune system. RA has been associated with dysbiosis of the gut microbiota. Patients with RA treated with DMARDs show partial restoration of eubiotic gut microbiome. Hence, it is essential to understand the impact of DMARDs on the microbial composition and its consequent influences on the host immune system to identify novel therapies for RA. In this review, we discuss the importance of antirheumatic-drug-induced host microbiota modulations and possible probiotics that can generate eubiosis.
CAM-type femoroacetabular impingement in male elite junior cross-country skiers and non-athlete controls: a cross-sectional MRI study
Sveen, Simen Andreas , Martin, R. Kyle , Alhaug, Eivind, Martin, Kyle, Engebretsen, Lars

Mayo Clinic

BMJ Open Sport & Exercise Medicine | July 30, 2019 | Volume: 5 | Issue: 1 | Pages: e000530

10.1136/bmjsem-2019-000530 | PMID 31423322 Get It

Objectives Cross-country (CC) skiing consists of two main techniques: classic and skating. Hip motion during the skating technique is similar to that in ice skating and is considered a risk factor for femoroacetabular impingement (FAI) in ice hockey players. We aimed to compare the presence of CAM-type FAI in a cohort of elite junior CC (EJCC) skiers with a control group of non-athlete (NA) high school students. Methods Observational cohort study: EJCC skiers and NAs were recruited from a sports school and a regular high school, respectively. Baseline demographics and training history were obtained via a questionnaire. Bilateral hip MRI was performed and the alpha angle was measured in three planes. CAM deformity was defined as an alpha angle>55° on at least two MRI planes per hip. Results A total of 20 EJCC skiers and 10 NAs participated. All participants were male, aged 16–19 years. Average training volume was 528.10±68.34 hours per year for the EJCC skiers compared with 153.50±57.09 for the NAs (p<0.001). The prevalence of CAM deformity in at least one hip on MRI was 50% in both groups (10 CC skiers and 5 NAs). The average alpha angles were 52.4±6.1° in the EJCC group and 52.5±4.9° in the NA group (p=0.94). Conclusion Radiographic evidence of CAM-type FAI was not more common in the CC skiers compared with NAs. The type, rather than volume or intensity of training, maybe a more important risk factor for the development of CAM-type FAI in young athletes.
Patient Attitudes Toward Testicular Prosthesis Placement After Orchiectomy
Srivatsav, Ashwin , Balasubramanian, Adithya , Butaney, Mohit , Thirumavalavan, Nannan , McBride, J. Abram, Gondokusumo, Jabez, Lipshultz, Larry I. , Pastuszak, Alexander W.

Mayo Clinic

American Journal of Men's Health | July 30, 2019 | Volume: 13 | Issue: 4 | Pages: No page available

10.1177/1557988319861019 | PMID 31359823 Get It

Orchiectomy is the standard of care for many testicular conditions. Testicular prosthesis placement (TPP) can mitigate psychosocial burden, restore self-image, and improve quality of life for patients requiring orchiectomy. Limited data exist regarding patient attitudes and counseling on TPP in the United States. The objective of this study was to characterize patient experiences after TPP, rationale for pursuing/declining TPP, and satisfaction levels. Patients with a history of urologic conditions warranting orchiectomy were identified and sent an anonymous survey addressing demographics, pre/post counseling, attitudes toward TPP, satisfaction rates, and postoperative complications. Sixteen percent (76/480) of patients completed the survey. Of these, 50.8% (32/63) undergoing orchiectomy were counseled by their surgeon about TPP, and 22.2% (14/63) received a prosthesis. The most common reasons for declining TPP included lack of concern for cosmetic appearance and lack of counseling. Leading reasons for pursuing TPP included improving self-confidence and cosmetic appearance. Although 71% (10/14) of patients were satisfied with TPP, they did highlight areas for improvement. Twenty percent (2/10) felt their implant was too high, 60% (6/10) felt their implant was too firm, 10% (1/10) endorsed discomfort during sex, and 30% (3/10) felt that TPP did not match their size expectations. Despite these findings, 71% (10/14) reported that they would have TPP again and 79% (11/14) would recommend TPP to others. TPP improves body image and quality of life following orchiectomy. Provider counseling plays an important role in influencing a patient’s decision to undergo TPP. Areas of improvement include implant positioning and more effective replication of testicular consistency.